Edward Neuwelt
American neurologist and neurosurgeon
- 1 min read
- 3 chapters
Explore on Lably
ToursExplore Lably’s 3D toursEducation and career
Neuwelt received his medical degree from the University of Colorado School of Medicine in Denver and completed his residency in neurosurgery at the University of Texas Southwestern Medical School in Dallas, Texas. He then completed research fellowships in neuro-oncology and neurosurgery at the National Cancer Institute, National Institutes of Health, and then another at Queen Square Hospital in London, England.
Neuwelt joined OHSU in 1981 as an assistant professor of neurology and neurosurgery. He became a full professor in 1990. He also holds a joint appointment at the Portland Veterans Affairs Medical Center, where he directs the Blood-Brain Barrier Program.
Sign in to keep reading
2 more chapters are free with a Lably account.
Research
Neuwelt's research has focused on developing new treatments for brain tumors, including the use of chemotherapy. He has also studied the blood-brain barrier, a protective barrier that prevents many drugs from reaching the brain. Neuwelt has developed techniques for temporarily opening the blood-brain barrier to allow drugs to reach brain tumors more effectively.
Later research
In the later years of his research career, Neuwelt focused on the use of iron oxide nanoparticles to diagnose central nervous system inflammatory diseases and primary central nervous system lymphoma. He also led the development and clinical trials of a new method to protect children from high-frequency hearing loss caused by chemotherapy treatment of pediatric tumors, using sodium thiosulfate.
His research resulted in the successful licensure of sodium thiosulfate by the Food and Drug Administration in 2023, making it the first drug approved to prevent hearing loss in children receiving cisplatin chemotherapy.